Pharma Stocks Plunge on Trump Tariff Threat

New Delhi:  Shares of Pharmaceutical companies on Friday tumbled up to 10 per cent amid reports that the Trump Administration will soon announce tariffs on pharma imports and emphasised that the measures will be “unprecedented”.

According to reports, President Trump has said that tariffs on pharmaceuticals and semiconductors will be announced shortly, emphasising that the measures on pharmaceutical imports will be unprecedented.

The US has announced 26 per cent reciprocal tariffs on India saying New Delhi imposes high import duties on American goods.

Reacting to the reports the stock of Aurobindo Pharma plunged 11 per cent to Rs 1,049.85 apiece on the, Laurus Labs tumbled 9.5 per cent to Rs 561.55, Ipca labs decreased 9.3 per cent to Rs 1,357.80, Lupin dipped 8.41 per cent to Rs 1,918.20, Biocon 7.03 per cent to Rs 321.25, and Cipla declined 7 per cent to Rs 1,390.35.

In addition, Marksans Pharma’s shares depreciated 6.7 per cent to Rs 217.40 per piece, Dr Reddys Laboratories declined 6.5 per cent to Rs 1,076.40 — also its 52-week low — Shilpa Medicare fell 6.4 per cent to Rs 633, and Sun Pharmaceutical Industries slipped 6.33 per cent to Rs 1,658.

Also, the scrip of Gland Pharma dipped 6 per cent to Rs 1,468.25 per share, Ajanta Pharma fell 5.4 per cent to Rs 2,480.05, Wockhardt depreciated by 5 per cent to hit a lower circuit band of Rs 1,347.55 on the exchange.

In Morning trade on Friday, the BSE healthcare index declined 1,347.88 points or 3.22 per cent to 40,522.91, while the 30-share BSE Sensex slumped 680.18 points or 0.89 per cent to 75,615.18.

Earlier, the Trump administration had exempted pharmaceuticals and semiconductors from the reciprocal tariff policy. Accordingly, shares of Pharmaceutical companies on Thursday had settled with gains of as much as 7 per cent.

Related Posts

Yashoda Medicity Successfully Performs High-Risk Kidney Transplant in 28-Year- Old Woman

The Team Meticulously averted the Risk of Thrombosis, Husband was Donor Delhi/NCR : Doctors at Yashoda Medicity have successfully performed a high-risk kidney transplant in a 28-year-old woman with Antiphospholipid…

Avacta delivers two clinical stage peptide-drug conjugates to target delivery of toxic payloads into the tumour microenvironment

Avacta, a UK-based clinical stage biotech, is differentiated clinical-stage oncology specialist, increasingly defined by continuing progress with its second-generation pre|CISION tumour-activated Peptide Drug Conjugate (PDC) platform. The lead Gen Two…

Leave a Reply

Your email address will not be published. Required fields are marked *

You Missed

Yashoda Medicity Successfully Performs High-Risk Kidney Transplant in 28-Year- Old Woman

Yashoda Medicity Successfully Performs High-Risk Kidney Transplant in 28-Year- Old Woman

Avacta delivers two clinical stage peptide-drug conjugates to target delivery of toxic payloads into the tumour microenvironment

Avacta delivers two clinical stage peptide-drug conjugates to target delivery of toxic payloads into the tumour microenvironment

US FDA approves first gene therapy for paediatric patients with Sanfilippo syndrome type A

US FDA approves first gene therapy for paediatric patients with Sanfilippo syndrome type A

Technology and accessibility are key to growth of advanced treatment of heart diseases, says expert

Technology and accessibility are key to growth of advanced treatment of heart diseases, says expert

Puresta launches EVERQ, AI-powered skin-health platform

Puresta launches EVERQ, AI-powered skin-health platform

Stem cell therapy for autism only in approved clinical trials: Centre

Stem cell therapy for autism only in approved clinical trials: Centre